Lucanthone 是一种 Apurinic 核酸内切酶-1 的抑制剂。

Lucanthone is an inhibitor of Apurinic endonuclease-1 (APE-1).

Lucanthone is a novel inhibitor of autophagy that induces cathepsin D-mediated apoptosis. Cell viability is measured by MTT assay to investigate the anticancer activity of Lucanthone. Lucanthone reduces cell viability to a similar extent in a panel of seven breast cancer cell lines. In addition, a direct comparison reveals that Lucanthone is significantly more potent than Chloroquine (CQ) at reducing breast cancer cell viability with a mean IC50 of 7.2 μM versus 66 μM for CQ. Measurement of cell viability in two representative cell lines (MDA-MB-231 and BT-20) by ATPlite assay and trypan blue exclusion reveals comparable results[2].

Cell viability is assessed by MTT assay. Cells are seeded into 96-well microculture plates at 10,000 cells per well and allowed to attach for 24 h. Cells are then treated with Lucanthone (0, 0.5, 1, 5, 10, 20 and 40 μM), Chloroquine, Vorinostat, or combinations for 72 h. Following drug treatment, MTT is added and cell viability is quantified using a BioTek microplate reader. Effects on cell viability are also determined by measuring ATP levels using the ATPlite assay system and by trypan blue exclusion. Pro-apoptotic effects following in vitro drug exposure are quantified by propidium iodide (PI) staining and fluorescence-activated cell sorting (FACS) analysis of sub-G0/G1 DNA content[2]

479-50-5

C20H24N2OS

340.49

Lucanthonum;硫蒽酮;硫坎酮;Lucantona

DMSO:25 mg/mL),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years